Last reviewed · How we verify
BC106 insulin lispro — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
BC106 insulin lispro (BC106 insulin lispro) — Adocia.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| BC106 insulin lispro TARGET | BC106 insulin lispro | Adocia | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- BC106 insulin lispro CI watch — RSS
- BC106 insulin lispro CI watch — Atom
- BC106 insulin lispro CI watch — JSON
- BC106 insulin lispro alone — RSS
Cite this brief
Drug Landscape (2026). BC106 insulin lispro — Competitive Intelligence Brief. https://druglandscape.com/ci/bc106-insulin-lispro. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing